Hematological and cytogenetic responses to STI571 therapy in chronic myeloid leukemia

Hematological and cytogenetic responses to STI571 therapy in chronic myeloid leukemia

Chronic Myeloid Leukemia (CML), a malignancy/ cancer of the white blood cells (leukocytes), where in there is excessive multiplication of myeloid stem cells within the bone marrow, is caused by the Bcr-Abl tyrosine kinase, the product of the Philadelphia Chromosome. The hallmark of CML is the Philad...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biosciences, biotechnology research Asia biotechnology research Asia, 2008-12, Vol.5 (2), p.753-756
Hauptverfasser: Dutta, A K, Ganesh, N, Sah, N K
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 756
container_issue 2
container_start_page 753
container_title Biosciences, biotechnology research Asia
container_volume 5
creator Dutta, A K
Ganesh, N
Sah, N K
description Chronic Myeloid Leukemia (CML), a malignancy/ cancer of the white blood cells (leukocytes), where in there is excessive multiplication of myeloid stem cells within the bone marrow, is caused by the Bcr-Abl tyrosine kinase, the product of the Philadelphia Chromosome. The hallmark of CML is the Philadelphia chromosome, which is present in more than 95% of patients. Imatinib mesylate, formerly known as STI-571 is a selective inhibitor of this kinase. A total of 25 patients had received imatinib mesylate therapy formed the subjects of this study. Patients were evaluated for cytogenetic and hematologic responses. Imatinib has shown remarkable clinical activity in patients with chronic myeloid leukemia. This study indicated that STI-571 has shown higher response rates compared with other therapy.
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_20498517</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20498517</sourcerecordid><originalsourceid>FETCH-LOGICAL-p101t-e5238161a833b9533e7e494d468ad76b211775efcc6b611385bc9ce3cc6157543</originalsourceid><addsrcrecordid>eNotjL1qwzAYADW0kJDmHTR1M-iz_qwxhLYJBDo0mYMsf0nUyJJryYPfvoF2Og6OeyJLZjSvoBZyQdY5fzPGamaYBliS0w57W1JIV-9soDZ21M0lXTFi8Y6OmIcUM2ZaEv067qUGWm442mGmPlJ3G1N8ZP2MIfmOBpzu2Hv7Qp4vNmRc_3NFTu9vx-2uOnx-7LebQzUAg1KhrHkDCmzDeWsk56hRGNEJ1dhOq7YG0FrixTnVKgDeyNYZh_zhILUUfEVe_77DmH4mzOXc--wwBBsxTflcM2EaCZr_Amk_TXw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20498517</pqid></control><display><type>article</type><title>Hematological and cytogenetic responses to STI571 therapy in chronic myeloid leukemia</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Dutta, A K ; Ganesh, N ; Sah, N K</creator><creatorcontrib>Dutta, A K ; Ganesh, N ; Sah, N K</creatorcontrib><description>Chronic Myeloid Leukemia (CML), a malignancy/ cancer of the white blood cells (leukocytes), where in there is excessive multiplication of myeloid stem cells within the bone marrow, is caused by the Bcr-Abl tyrosine kinase, the product of the Philadelphia Chromosome. The hallmark of CML is the Philadelphia chromosome, which is present in more than 95% of patients. Imatinib mesylate, formerly known as STI-571 is a selective inhibitor of this kinase. A total of 25 patients had received imatinib mesylate therapy formed the subjects of this study. Patients were evaluated for cytogenetic and hematologic responses. Imatinib has shown remarkable clinical activity in patients with chronic myeloid leukemia. This study indicated that STI-571 has shown higher response rates compared with other therapy.</description><identifier>ISSN: 0973-1245</identifier><language>eng</language><ispartof>Biosciences, biotechnology research Asia, 2008-12, Vol.5 (2), p.753-756</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids></links><search><creatorcontrib>Dutta, A K</creatorcontrib><creatorcontrib>Ganesh, N</creatorcontrib><creatorcontrib>Sah, N K</creatorcontrib><title>Hematological and cytogenetic responses to STI571 therapy in chronic myeloid leukemia</title><title>Biosciences, biotechnology research Asia</title><description>Chronic Myeloid Leukemia (CML), a malignancy/ cancer of the white blood cells (leukocytes), where in there is excessive multiplication of myeloid stem cells within the bone marrow, is caused by the Bcr-Abl tyrosine kinase, the product of the Philadelphia Chromosome. The hallmark of CML is the Philadelphia chromosome, which is present in more than 95% of patients. Imatinib mesylate, formerly known as STI-571 is a selective inhibitor of this kinase. A total of 25 patients had received imatinib mesylate therapy formed the subjects of this study. Patients were evaluated for cytogenetic and hematologic responses. Imatinib has shown remarkable clinical activity in patients with chronic myeloid leukemia. This study indicated that STI-571 has shown higher response rates compared with other therapy.</description><issn>0973-1245</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNotjL1qwzAYADW0kJDmHTR1M-iz_qwxhLYJBDo0mYMsf0nUyJJryYPfvoF2Og6OeyJLZjSvoBZyQdY5fzPGamaYBliS0w57W1JIV-9soDZ21M0lXTFi8Y6OmIcUM2ZaEv067qUGWm442mGmPlJ3G1N8ZP2MIfmOBpzu2Hv7Qp4vNmRc_3NFTu9vx-2uOnx-7LebQzUAg1KhrHkDCmzDeWsk56hRGNEJ1dhOq7YG0FrixTnVKgDeyNYZh_zhILUUfEVe_77DmH4mzOXc--wwBBsxTflcM2EaCZr_Amk_TXw</recordid><startdate>20081201</startdate><enddate>20081201</enddate><creator>Dutta, A K</creator><creator>Ganesh, N</creator><creator>Sah, N K</creator><scope>7QO</scope><scope>7T5</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>20081201</creationdate><title>Hematological and cytogenetic responses to STI571 therapy in chronic myeloid leukemia</title><author>Dutta, A K ; Ganesh, N ; Sah, N K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p101t-e5238161a833b9533e7e494d468ad76b211775efcc6b611385bc9ce3cc6157543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Dutta, A K</creatorcontrib><creatorcontrib>Ganesh, N</creatorcontrib><creatorcontrib>Sah, N K</creatorcontrib><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Biosciences, biotechnology research Asia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dutta, A K</au><au>Ganesh, N</au><au>Sah, N K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hematological and cytogenetic responses to STI571 therapy in chronic myeloid leukemia</atitle><jtitle>Biosciences, biotechnology research Asia</jtitle><date>2008-12-01</date><risdate>2008</risdate><volume>5</volume><issue>2</issue><spage>753</spage><epage>756</epage><pages>753-756</pages><issn>0973-1245</issn><abstract>Chronic Myeloid Leukemia (CML), a malignancy/ cancer of the white blood cells (leukocytes), where in there is excessive multiplication of myeloid stem cells within the bone marrow, is caused by the Bcr-Abl tyrosine kinase, the product of the Philadelphia Chromosome. The hallmark of CML is the Philadelphia chromosome, which is present in more than 95% of patients. Imatinib mesylate, formerly known as STI-571 is a selective inhibitor of this kinase. A total of 25 patients had received imatinib mesylate therapy formed the subjects of this study. Patients were evaluated for cytogenetic and hematologic responses. Imatinib has shown remarkable clinical activity in patients with chronic myeloid leukemia. This study indicated that STI-571 has shown higher response rates compared with other therapy.</abstract><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0973-1245
ispartof Biosciences, biotechnology research Asia, 2008-12, Vol.5 (2), p.753-756
issn 0973-1245
language eng
recordid cdi_proquest_miscellaneous_20498517
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
title Hematological and cytogenetic responses to STI571 therapy in chronic myeloid leukemia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T16%3A28%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hematological%20and%20cytogenetic%20responses%20to%20STI571%20therapy%20in%20chronic%20myeloid%20leukemia&rft.jtitle=Biosciences,%20biotechnology%20research%20Asia&rft.au=Dutta,%20A%20K&rft.date=2008-12-01&rft.volume=5&rft.issue=2&rft.spage=753&rft.epage=756&rft.pages=753-756&rft.issn=0973-1245&rft_id=info:doi/&rft_dat=%3Cproquest%3E20498517%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20498517&rft_id=info:pmid/&rfr_iscdi=true